# Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

> **NCT01579630** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Taipei Veterans General Hospital, Taiwan** · enrollment: 52 (actual)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** Pemetrexed 500mg/m2 iv
- **DRUG:** Pemetrexed 500mg/m2 iv and Gefitinib 250 mg

## Key facts

- **NCT ID:** NCT01579630
- **Lead sponsor:** Taipei Veterans General Hospital, Taiwan
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-03
- **Primary completion:** 2013-06
- **Final completion:** 2014-06
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2014-04-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01579630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01579630, "Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01579630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*